This paper examines the findings from three research projects that dealt
with the passage of endocrine disrupting compounds (EDCs) and pharmaceuticals and personal care products (PPCPs) compounds through conventional wastewater and
advanced reuse treatment processes.
The first study was an evaluation, funded by the Water Environment Research Foundation, of the
passage of PPCP compounds through the aqueous phase of full-scale wastewater
facilities located in the arid Southwestern United States. The data demonstrate how
compound passage can be related to the solids retention time (SRT) of the activated
sludge process. The study also evaluated the impact of wastewater granular media filters
and MF/RO that were part of some of the study process trains and compared performance
of a full-scale activated sludge facility with side-by-side operation of a pilot MBR.
The second study was an evaluation of monitoring methods to ensure the integrity of
reverse osmosis (RO) membranes during water reclamation predominantly funded by the
California Department of Water Resources. RO pilot testing was performed by the City
of San Diego and MWH using tertiary treated wastewater from the North City Water
Reclamation Plant located in San Diego County, California. Presented results focus on
the passage of EDC and PPCP compounds through four different vendor supplied RO
membranes and the impact of RO staging and membrane breaching on compound
passage.
The third study was part of an alternative water source program funded by the City of San
Diego Water Department in partnership with the San Diego County Water Authority and
the Metropolitan Water District of Southern California. The work, performed earlier at
the same site location as the second study, evaluated UV/peroxide treatment as an
additional barrier against the passage of EDCs and PPCPs in RO treated tertiary
wastewater effluent. The RO effluent was spiked with N-nitrosodimethylamine (NDMA)
and eight (8) EDC/PPCP target compounds in order to determine the reduction in the
passage of EDCs and PPCPs at the dose needed to achieve one-log reduction of NDMA. Includes 11 references, tables, figure.
| Edition : | Vol. - No. |
| File Size : | 1
file
, 260 KB |
| Note : | This product is unavailable in Ukraine, Russia, Belarus |
| Number of Pages : | 15 |
| Published : | 11/01/2007 |
